Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACIFIC: Bexicaserin in DEE
NCT05364021Phase 2Completed
- Sponsor
- Longboard Pharmaceuticals
- Start
- Mar 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in developmental and epileptic encephalopathy (DEE), Dravet syndrome and Lennox-Gastaut syndrome (LGS) comparing LP352 with Placebo (2 arms). Primary endpoints: Treatment-emergent Adverse Events at Day 75, Percent Change from Baseline in Observed Countable Motor Seizure Frequency at Day 75 and 2 more. Started Mar 2022; status: completed.
02
Drugs
bexicaserin
03
Conditions
developmental and epileptic encephalopathy (DEE)Dravet syndromeLennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on NCT05364021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05364021.